Premature Ovarian Insufficiency Medical Services in China

Premature Ovarian Insufficiency (POI), formerly known as premature ovarian failure, is a clinical syndrome characterized by the loss of ovarian function before age 40. It is defined by amenorrhea (absence of menstruation) for at least four consecutive months, elevated follicle-stimulating hormone (FSH) levels (>25 IU/L on two occasions >4 weeks apart), and low estradiol levels. Unlike natural menopause, POI is not always permanent—approximately 5–10% of affected individuals experience intermittent ovarian activity and even spontaneous pregnancy. Pathogenically, POI results from accelerated depletion or dysfunction of ovarian follicles due to diverse mechanisms: genetic abnormalities (e.g., X-chromosome anomalies like Turner syndrome or FMR1 premutation), autoimmune disorders (e.g., associated with thyroiditis or Addison’s disease), iatrogenic causes (chemotherapy, radiation, or ovarian surgery), metabolic conditions (e.g., galactosemia), infections (rare, e.g., mumps oophoritis), or idiopathic origins (accounting for ~75–90% of cases). Epidemiologically, POI affects approximately 1% of women under age 40, 0.1% under age 30, and 0.01% under age 20. Incidence appears consistent across ethnic groups, though underdiagnosis remains common due to symptom variability and lack of routine screening. Key risk factors include family history of POI or early menopause, prior gonadotoxic treatments, autoimmune polyglandular syndromes, certain chromosomal disorders, and smoking (which may accelerate follicular atresia). Beyond reproductive implications—infertility being the most distressing consequence—POI significantly impacts long-term health and quality of life. Estrogen deficiency increases risks of osteoporosis, cardiovascular disease, cognitive decline, and genitourinary syndrome of menopause (vaginal atrophy, dyspareunia, urinary urgency). Psychologically, patients frequently report anxiety, depression, diminished self-esteem, sexual dysfunction, and grief over lost fertility and altered life trajectory. Early diagnosis and multidisciplinary management—including hormonal, psychological, bone health, and fertility preservation support—are essential to mitigate morbidity and optimize well-being. Patient education, peer support, and shared decision-making are integral components of holistic care in reproductive medicine departments.

Premature Ovarian Insufficiency (POI), defined as the loss of ovarian function before age 40, affects approximately 1% of women and is characterized by amenorrhea, elevated gonadotropins (FSH >25 IU/L on two occasions >4 weeks apart), and estrogen deficiency. Diagnosis requires exclusion of transient causes (e.g., pregnancy, hyperprolactinemia, thyroid dysfunction) and autoimmune or genetic etiologies (e.g., FMR1 premutation, Turner mosaicism, adrenal autoantibodies). Management in the Department of Reproductive Medicine is multidisciplinary, patient-centered, and aims to mitigate long-term health risks—including osteoporosis, cardiovascular disease, genitourinary syndrome of menopause (GSM), and psychological morbidity—while addressing fertility preservation and reproductive goals.

Conservative treatment forms the cornerstone of POI management and emphasizes non-pharmacologic, lifestyle-integrated strategies. Patients undergo comprehensive baseline assessment including dual-energy X-ray absorptiometry (DXA) for bone mineral density (BMD), lipid profile, fasting glucose, and cardiovascular risk stratification. Nutritional counseling focuses on calcium (1200 mg/day) and vitamin D (800–1000 IU/day) supplementation, alongside Mediterranean-style dietary patterns to support vascular and metabolic health. Weight-bearing and resistance exercise (≥150 min/week) are prescribed to preserve BMD and reduce fracture risk. Smoking cessation and alcohol moderation are strongly advised, given their synergistic negative impact on ovarian reserve and bone turnover. Psychological support—including cognitive behavioral therapy (CBT), peer-led support groups, and fertility counseling—is integral; up to 60% of women with POI report clinically significant anxiety or depression, often linked to identity disruption and perceived loss of reproductive autonomy.

Pharmacotherapy is primarily hormone replacement therapy (HRT), initiated as soon as diagnosis is confirmed and continued until the average age of natural menopause (~51 years), unless contraindicated. Transdermal estradiol (e.g., 0.05–0.1 mg/day patch or 25–50 μg/day gel) combined with oral or vaginal micronized progesterone (100–200 mg/day for 12–14 days/month in women with an intact uterus) is preferred over oral conjugated estrogens due to lower thrombotic risk and more physiological estrogen metabolism. For women with contraindications to systemic HRT (e.g., active thrombophilia, history of estrogen-sensitive malignancy), ultra-low-dose vaginal estriol (0.03 mg twice weekly) may alleviate GSM symptoms but does not confer systemic protection. Selective estrogen receptor modulators (SERMs) like raloxifene are not recommended as monotherapy in POI due to insufficient data on bone or cardiovascular outcomes and lack of endometrial protection. Bisphosphonates (e.g., alendronate 70 mg/week) are reserved for women with established osteoporosis (T-score ≤ −2.5) or fragility fracture, not for primary prevention. Androgen supplementation (e.g., dehydroepiandrosterone 25 mg/day) remains investigational and is not routinely endorsed outside clinical trials due to inconsistent efficacy and safety concerns regarding hepatic metabolism and lipid profiles.

Surgical intervention has no role in the direct management of POI itself, as it is a functional—not structural—disorder. However, laparoscopic oophorectomy or ovarian wedge resection may be indicated in rare cases where coexisting pathology (e.g., large benign cysts, endometriomas causing chronic pelvic pain) necessitates surgical evaluation. Importantly, ovarian tissue cryopreservation is not applicable in established POI, as follicular depletion is typically complete; however, in adolescents or young women with suspected early-stage POI (e.g., after chemotherapy or in autoimmune polyglandular syndrome), referral for experimental ovarian cortex cryopreservation may be considered prior to irreversible follicle loss—though success rates remain low (<5% live birth rate to date) and require IRB-approved protocols.

Treatment advantages in China reflect robust integration of evidence-based Western medicine with standardized traditional Chinese medicine (TCM) adjuncts under regulatory oversight. The National Health Commission mandates uniform diagnostic criteria and HRT protocols across Class III Grade A hospitals, ensuring consistent access to high-quality transdermal estradiol and micronized progesterone formulations. China’s centralized pharmacovigilance system enables real-time monitoring of HRT safety, contributing to one of the lowest reported venous thromboembolism rates among HRT users globally (<0.5 per 1000 woman-years). Moreover, TCM modalities—including acupuncture (ST36, SP6, CV4 stimulation shown in RCTs to improve vasomotor symptom scores by 35–40%) and standardized herbal formulas (e.g., Zuo Gui Wan for kidney-yin deficiency pattern) —are integrated into national POI guidelines when evidence supports symptom relief, provided they do not interfere with hormonal assays or anticoagulant therapy. Advanced reproductive technologies—including third-generation IVF with preimplantation genetic testing (PGT-A) for chromosomal screening—are widely accessible and subsidized under provincial health insurance schemes for eligible couples pursuing donor oocyte cycles, which remain the only viable fertility option for most women with confirmed POI.

Recovery and long-term follow-up emphasize continuity of care. Patients are scheduled for annual visits including pelvic ultrasound (to monitor endometrial thickness during cyclic HRT), repeat DXA at 2 years if initial BMD is normal or earlier if abnormal, and reassessment of cardiovascular risk using QRISK3 or ASCVD calculators. HRT adherence is reinforced through digital health platforms (e.g., WeDoctor app reminders, teleconsultations), with >85% adherence rates reported in urban tertiary centers. Fertility counseling must be ongoing: while spontaneous conception occurs in ~5–10% of POI cases (often unpredictably), patients should understand that donor oocyte IVF offers the highest live birth rate (55–65% per transfer in China’s top-tier centers). Bone health maintenance continues lifelong—calcium/vitamin D supplementation persists beyond HRT cessation, and weight-bearing exercise remains non-negotiable. Finally, transition to menopause-specialized care after age 51 ensures seamless management of aging-related comorbidities without therapeutic gaps. With coordinated, culturally attuned, and scientifically grounded care, women with POI in China achieve excellent quality-of-life outcomes, preserved skeletal integrity, and empowered reproductive decision-making.